home / stock / alxo / alxo news

ALXO News and Press, ALX Oncology Holdings Inc. From 11/29/22

Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALXO - ALX Oncology Appoints Scott Garland to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to ...
ALXO - ALX Oncology GAAP EPS of -$0.87 misses by $0.08

ALX Oncology press release ( NASDAQ: ALXO ): Q3 GAAP EPS of -$0.87 misses by $0.08 . Cash, cash equivalents and investments were $293.1 million as of September 30, 2022. For further details see: ALX Oncology GAAP EPS of -$0.87 misses by $0.08

ALXO - ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quar...

ALXO - ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the Company will be presenting clin...
ALXO - ALX Oncology inks up to $100M loan agreement to develop cancer drug evorpacept

ALX Oncology ( NASDAQ: ALXO ) said it signed an agreement with Oxford Finance and Silicon Valley Bank for up to $100M in non-dilutive financing to support the development of cancer drug candidate evorpacept. Under the agreement, ALX drew $10M of an initial $50M mi...

ALXO - ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a loan facility ...

ALXO - ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Pro...
ALXO - ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, Pr...

ALXO - ALX Oncology Announces Upcoming Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that management will participate in...

ALXO - ALX Oncology and Quantum Leap Healthcare Collaborative(TM) Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- ALX Oncolo...
Previous 10 Next 10